4.2 Article

Causes for Treatment Delays in Dystonia and Hemifacial Spasm: A Canadian Survey

期刊

CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
卷 38, 期 5, 页码 704-711

出版社

CANADIAN JOURNAL NEUROLOGICAL SCIENCES INC
DOI: 10.1017/S0317167100012270

关键词

-

资金

  1. Allergan Inc.
  2. Allergan
  3. Merz
  4. Novartis
  5. IMPAX Pharmaceuticals
  6. Canadian Institute for Health Research
  7. National Institutes of Health
  8. Parkinson Research Consortium
  9. MJF Foundation
  10. Medtronic

向作者/读者索取更多资源

Background: Dystonia must be accurately diagnosed so that treatment can be administered promptly. However, dystonia is a complex disorder, with variable presentation, which can delay diagnosis. Methods: Data were gathered by questionnaire from 866 patients with dystonia or hemifacial spasm (HFS) treated in 14 movement disorders centres in Canada injecting botulinum toxin, to better understand the path to diagnosis, wait times and obstacles to treatment. Results: Most participants were female (64.1%), mean age was 58 years, and patients consulted an average of 3.2 physicians before receiving a dystonia or HFS diagnosis. Many patients (34%) received other diagnoses before referral to a movement disorders clinic, most commonly stress (42.7%). A variety of treatments were often received without a diagnosis. The mean lag time between symptom onset and diagnosis was 5.4 years. After the decision to use botulinum toxin, patients waited a mean of 3.1 months before treatment. The most common diagnoses were cervical dystonia (51.6% of patients), HFS (20.0%) and blepharospasm (9.8%). Conclusions: Survey results show that diagnosis of dystonias or of HFS, and therefore, access to treatment, is delayed. An educational program for primary care physicians may be helpful to decrease the time to diagnosis and referral to a specialist centre for treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据